CD19 and lymphoma: These selected papers encompassed a total of 977 lymphoma patients undergoing anti-CD19 CAR T-cell therapy and underwent a thorough and detailed analysis to extract pertinent subjective data for inclusion in the meta-analysis (Table 2).